Dihydropyrimidin-2-one compounds and medical use thereof
A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
2. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claims 1 and 2 - 8 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
10. A method of treating an autoimmune disease selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, type I diabetes, and graft versus host disease comprising administering to a human an effective amount of a compound of any one of claims 1 and 2 - 8 , or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the autoimmune disease is inflammatory bowel disease wherein the inflammatory bowel disease is Crohn's disease.
12. The method of claim 10 , wherein the autoimmune disease is inflammatory bowel disease wherein the inflammatory bowel disease is ulcerative colitis.
13. A method of treating diabetes comprising administering to a human an effective amount of a compound of any one of claims 1 and 2 - 8 , or a pharmaceutically acceptable salt thereof.
14. The method of claim 10 , wherein the autoimmune disease is psoriasis.
15. A compound selected from the group consisting of:
16. The compound of claim 15 , wherein the compound is:
17. The compound of claim 15 , wherein the compound is:
18. The compound of claim 15 , wherein the compound is:
19. The compound of claim 15 , wherein the compound is:
20. The compound of claim 15 , wherein the compound is:
21. The compound of claim 15 , wherein the compound is:
22. The compound of claim 15 , wherein the compound is:
23. A pharmaceutical composition comprising a compound of any one of claims 15 - 22 , and a pharmaceutically acceptable carrier.
24. A method of treating an autoimmune disease selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, type I diabetes, and graft versus host disease comprising administering to a human an effective amount of a compound of any one of claims 15 - 22 .
25. The method of claim 24 , wherein the autoimmune disease is inflammatory bowel disease wherein the inflammatory bowel disease is Crohn's disease.
26. The method of claim 24 , wherein the autoimmune disease is inflammatory bowel disease wherein the inflammatory bowel disease is ulcerative colitis.
27. The method of claim 24 , wherein the autoimmune disease is psoriasis.
28. A method of treating diabetes comprising administering to a human an effective amount of a compound of any one of claims 15 - 22 .